trial · primary record
Biospecimen Collection
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 30 |
| Primary completion | 2027-06-30 |
| Primary endpoint | Safety and tolerability of monsunetuzumab+polatuzumab vedotin+lenalidomide for determination of recommended phase 2 dose |
| Registry ID | NCT06015880 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:20.314Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06015880
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.